EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma.
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). It has been proved to be associated with tumor i...
Main Authors: | Li Tian, Yang Zhang, Yu Chen, Min Cai, Hailong Dong, Lize Xiong |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3596336?pdf=render |
Similar Items
-
Role of emmprin in endometrial cancer
by: Nakamura Keiichiro, et al.
Published: (2012-05-01) -
Extracellular vesicles originating from glioblastoma cells increase metalloproteinase release by astrocytes: the role of CD147 (EMMPRIN) and ionizing radiation
by: Nicholas W. Colangelo, et al.
Published: (2020-02-01) -
EMMPRIN expression is associated with metastatic progression in osteosarcoma
by: Han-Soo Kim, et al.
Published: (2021-09-01) -
EMMPRIN and fascin expression in non-small cell lung carcinoma
by: Kefeli Mehmet, et al.
Published: (2010-12-01) -
Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasis.
by: Zhiquan Huang, et al.
Published: (2014-01-01)